Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease.
Obesity is currently an epidemic, and the prevalence of cardiovascular risk factors is increasing dramatically as a result. Visceral adiposity is correlated with a proinflammatory and prothrombotic state that is believed to promote atherosclerosis and acute coronary syndromes. This article will review clinical trials on the effects of weight loss and pharmacotherapy on obesity associated inflammatory and thrombotic markers linked with cardiovascular disease.
Miller
Wendy M
WM
Beaumont Health Center, Weight Control Center, Division of Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, 4949 Coolidge Highway, Royal Oak, MI 48078, USA. wmiller@beaumont.edu
Nori Janosz
Katherine E
KE
Yanez
Jose
J
McCullough
Peter A
PA
D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D006801:Humans; D007249:Inflammation / Q000209:etiology*; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D015431:Weight Loss